Model-Driven Hybrid AI Framework for End-to-End Autonomous Decision-Making in Drug Development
Hyunjung LeeiD, Hongmei KangiD, Woojin JungiD, Hyojin ChoiD, Sungwoo GooiD, Hwi-yeol YuniD, Min‐Gul KimiD, Jung‐woo ChaeiD, Sang-Min ParkiD, Soyoung LeeiD, Jae Hyun KimiD, Sangkeun JungiD
Abstract
Decision-making in drug development spans heterogeneous stages from molecular design to clinical optimization, yet computer-aided workflows across stages remain fragmented, limiting traceability from evidence-derived clinical questions to simulation scenarios and decision endpoints. We present a model-driven hybrid AI framework for end-to-end decision support that treats PICO (Participants, Intervention, Comparison, Outcome) as a machine-actionable specification to define scenarios and align endpoints across modules. Given a PICO-defined clinical question and a drug SMILES, the framework infers PBPK-ready parameters from structure, generates exposure via mechanistic PBPK simulation, and links exposure outputs to clinic-facing therapeutic drug monitoring (TDM) decision support using an open-source NLME-based Clinical Pharmacokinetic Consultant Service (CPCS). We additionally implement an LLM-based PICO extraction layer to structure clinical abstracts into P/I/C/O elements for systematic evidence ingestion. Results include backbone verification for DTI-guided intrinsic clearance prediction under fold-error bounds and PBPK trajectory plausibility, and external validation of the hybrid AI-PBPK pipeline showing substantial dispersion for several endpoints. An input-controlled comparison between PhysioSim and PK-Sim on N = 9 drugs yields similarly degraded accuracy under identical AI-predicted inputs, suggesting upstream parameter quality as a dominant constraint. For evidence ingestion, prompting-only PICO extraction achieves F1 of 0.687 on EBM-NLP and 0.552 on TB-PICO. For clinical utility, CPCS improves TDM performance over a PKS baseline on phenobarbital and vancomycin, reducing MAPE by approximately 26-60% depending on configuration. Overall, the framework provides a modular, traceable blueprint linking evidence-defined questions to exposure simulation and TDM decision support while preserving mechanistic interpretability. Future work will integrate outcome-aligned time-to-event modeling and federated learning to close the PICO-to-outcome loop and improve parameter inference under multi-site governance.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An Artificial Intelligence Framework for Optimal Drug Design
G. Ramey, S. Vargas, … P. Bloomingdale·bioRxiv·Oct 29, 2022
- Prompt-to-Pill: Multi-Agent Drug Discovery and Clinical Simulation Pipeline
Ivana Vichentijevikj, Kostadin Mishev, Monika Simjanoska·Bioinformatics AdvancesPeer-reviewed·Dec 20, 2025
- An AI-agent-orchestrated grey-box Transformer framework for sparse pharmacokinetic curve reconstruction and pharmacometric model initialization
Jingcheng Chen, Jiacheng Wang, … Dongyang Liu·bioRxiv·May 27, 2026
- An AI-Assisted Workflow for Reconstruction, Extension, and Calibration of Quantitative Systems Pharmacology Models.
Igor Goryanin, Oleg V. Demin, Irina Goryanin·bioRxiv·Apr 7, 2026
- Hybrid Mechanistic-Neural Modeling of Concentration-Time Dynamics Generalizes Human Pharmacokinetics Prediction Across Unseen Chemical Space
Amitesh Badkul, Lianjin Cai, … Lei Xie·bioRxiv·Oct 8, 2026
- TRACEDD: A Tool-grounded Reasoning and Agentic Coordination for Explainable Drug Design
Sarveswara Rao Vangala, Vishnu Vardhan Kasturi, … Arijit Roy·bioRxiv·Sep 18, 2026